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The early steps in hepatitis B virus (HBV) infection, a human hepadnavirus, initiates from cell attachment followed by entry and delivery
of the genetic information to the nucleus. Despite the fact that these steps determine the virus-related pathogenesis, their molecular basis is
poorly understood. Cumulative data suggest that this process can be divided to cell attachment, endocytosis, membrane fusion and post-
fusion consecutive steps. These steps are likely to be regulated by the viral envelope proteins and by the cellular membrane, receptors and
extracellular matrix. In the absence of animal model for HBV, the duck hepadnavirus DHBV turned out to be a fruitful animal model.
Therefore data concerning the early, post-attachment steps in hepadnaviral entry are largely based on studies performed with DHBV in
primary duck liver hepatocytes. These studies are now starting to illuminate the mechanisms of hepadnavirus route of cell entry and to
provide some new insights on the molecular basis of the strict species specificity of hepadnavirus infection.D 2003 Elsevier B.V. All rights reserved.Keywords: Hepatitis B; Hepadnavirus; HBV infection1. Introduction
Hepatitis B virus (HBV), a human hepadnavirus, is an
enveloped DNA virus that primarily infects human hep-
atocytes. Viral infection may progress to acute or chronic
hepatitis, and may eventually cause cirrhosis and hepato-
cellular carcinoma (HCC) (reviewed in Ref. [1]). The
envelope of the Dane particle, the infectious virion, is
made of a cell-originated membrane containing the viral
envelope proteins called surface antigens (HBsAgs). The
inner nucleocapsid contains the viral DNA genome, the
viral polymerase/reverse transcriptase and accessory fac-
tors that originating from infected cells. In addition, the
serum of the infected individuals contains non-infectious
sub-viral particles that comprise over 90% of the total
particles.
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74100, Israel.HBV infection studies. Several human hepatocyte cell
lines retaining some of the hepatocyte markers are
available that support HBV transcription and replication
upon plasmid transfection. However, even these permis-
sive cell lines are not susceptible to HBV infection. An
inevitable conclusion is that the early steps of virus–cell
attachment and entry determine the viral tropism and
susceptibility.
The investigation of the mechanism of endocytosis and
membrane fusion for HBV is at its infancy. Following
endocytosis, and membrane fusion, the nucleocapsid rea-
ches the nucleus in yet poorly identified processes. At this
stage, the encased viral DNA enters the nucleus possibly via
the nuclear pore complex (NPC) [2,3]. Within the nucleus,
the relaxed circular viral DNA is converted to a covalently
closed circular DNA (cccDNA), the template for viral gene
expression and replication.
The earliest stage in HBV infection involves therefore
many distinct steps from cell recognition, attachment, endo-
cytosis, fusion and translocation of the genomic DNA to the
nucleus. The number of steps is expected to increase with the
fine resolution of the underlying molecular mechanisms. In
this review, we will cover the recent achievements in inves-
tigating the process of hepadnavirus attachment to the target
cells and the most immediate consequences.
Fig. 1. General structure of the hepadnavirus and its surface proteins. (A)
Schematic representation of the hepatitis B virion showing the viral DNA
covalently attached to the terminal protein of the viral polymerase/reverse
transcriptase (POL/RTase). This complex is enclosed by an inner
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Attempts were made to measure HBV recognition and
attachment to the existing HBV permissive hepatocyte cell
lines but no significant progress was made due to the fact
that these cells are refractory to HBV infection. Also, human
primary hepatocytes are only variably susceptible to infec-
tion and for a short period [4–7]. To improve susceptibility,
the permissive cell lines were cultivated under different
conditions. Improved HBV [4,8] and DHBV infection
[5,7] was obtained by the exposure of the cells to chemicals
such as dimethyl sulfoxide (DMSO) and to polyethylene
glycol (PEG). Combined treatment with DMSO and 100
AM 5-aza-2V-deoxycytidine further sensitized HepG2 to
HBV infection (our unpublished observation) as well as
avian hepatocytes to DHBV infection [9]. This protocol set
the stage for measuring HBV–cell attachment.
Several methods have been described to study HBV–
and DHBV–cell attachment [7,10–12]. However, due to
the transient nature of the attachment process, its study and
quantitative measurements turned out to be rather difficult.
We have recently utilized synthetic beads with conjugated
viral proteins to quantitatively evaluate virus–cell attach-
ment at a single cell resolution by light microscopy [8]. This
method permits to evaluate the attachment capacity of a
given cell and to categorize or separate cells based on
attachment competence. In addition to attachment, entry of
the HBV–protein conjugated beads into the cells can be
easily detected by scanning and transmission electron mi-
croscopy. It has been reported that envelope proteins as
particles are by far much better than the soluble proteins in
competing viral infection [13]. The presence of a large
number of viral conjugated proteins per bead is therefore
expected to improve the attachment kinetics. This improve-
ment is in particular important for tracking epitopes with
weak cell attachment activity. In addition, co-conjugation of
a mixture of ligands permits detection of cooperative
binding activity. Finally, use of beads that are readily
visualized allows real-time analysis of cell attachment.
Thus, immediate effects of viral attachment on cell behavior
and morphology can be monitored.
nucleocapsid and an outer envelope (double layered circle). A schematic
presentation of the viral membrane with the three different envelope
proteins is shown. Filled boxes represent transmembrane domains of the
surface proteins. Tree-like symbols represent glycosylation sites. The
preS1/preS2 domains are differentially lightened. Approximate location of
the QLDPAF sequence is also shown. (B) Schematic representation of HBV
surface proteins. Blank boxes correspond to the transmembrane (TM)
regions. The prominent HBVattachment epitope (amino acids 21–47 of the
preS1 domain) containing the QLDPAF sequence is shown. Also shown is
the location and sequence of the putative HBV fusion peptide. (C)
Schematic representation of DHBV surface proteins. The duCPD (gp180)
binding subdomain (amino acids 30–115 of the preS domain) consists of an
a-helical region (amino acids 86–115) conferring primary, low-affinity
binding and of a non-structured region (amino acids 30–86) that binds
sequentially to generate a high-affinity complex [32]. The p120 binding site
(amino acids 98–102 of preS domain) is also shown [34]. The host-
determining region (amino acids 22–37 of the preS domain) renders heron
HBV infectious to primary duck hepatocytes [36].3. The prominent HBV epitope mediating cell
attachment
The HBV envelope proteins consist of the small HBsAg
(SHBsAg, p24 and gp27), the middle HBsAg (MHBsAg,
gp33 and gp36) and the large HBsAg (LHBsAg, p39 and
gp42), all sharing the C-terminal 225 amino acids (Fig. 1). It
is well documented that LHBsAg, the quantitatively minor
envelope protein, plays the prominent role in cell attachment
and infection of hepadnaviruses. The unique N-terminal 109
or 120 amino acids of the LHBsAg, depending on the viral
subtype, named preS1, bears the major cell attachment
epitope. A number of cellular proteins were identified that
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23]. This epitope was functionally narrowed down to amino
acids 21–47 of preS1 [10]. Furthermore, by employing
synthetic peptides, it was found that this epitope is not only
required but also sufficient to attach specifically HepG2
cells [10,24–26]. Later by combined mutagenesis studies
and single cell attachment analysis, the QLDPAF sequence
within this epitope was found to be the crucial sequence for
cell attachment [8].
In light of the fact that HBV cell attachment and infection
are highly cell type specific, it was rather unexpected that
other proteins from viral, bacterial and cellular origin share
the minimal QLDPAF epitope. Most of the QLDPAF
proteins have a role in cell adhesion, cell-to-cell attachment
and membrane fusion [8]. This suggests that the QLDPAF
sequence may have a more general role in viral and
microbial infection and also in cell adherence and attach-
ment. To reconcile the general role of this epitope with the
narrow host range of HBV, one has to assume that variations
in this epitope and the adjacent sequences determine tissue
and species specificity of HBV. Consistent with this notion,
studies on HBV infection of primary human hepatocytes
revealed that an extended region within the preS1 sequence
mediates infection [27].
Interestingly, the X protein (pX) of HBV bears a similar
QLDPAR sequence at its N terminus. This pX region is
highly conserved yet mutational studies have not yet
assigned a particular function to this sequence. The similar-
ity with the preS1 attachment domain raises the intriguing
possibility that pX might be involved in cell attachment as
well. We have identified two EGF-repeats containing pro-
teins, FIBL-5 and FIBL-3, that bind a recombinant poly-
peptide containing the preS1 sequence and to a synthetic
peptide containing the 21–47 amino acids attachment
epitope. Expression of FIBL-5 is induced under conditions
whereby HepG2 cells are sensitized to HBV infection in
agreement with its possible involvement in mediating
HBV–cell attachment (our unpublished data). Interestingly,
FIBL-3 binds pX as well [28]. Thus, pX might have a role in
cell attachment that so far has been overlooked.4. Multivalent and cooperative HBV–cell attachment
Although the preS1 region contains the major cell
attachment epitope, a second epitope outside the preS1
region was detected that is involved in cell attachment [8].
Particles made solely of the small HBsAg specifically
attached cells albeit with a low efficiency possibly owing
to the presence of yet unidentified attachment epitope. As
expected, beads conjugated with the recombinant preS1
protein containing the prominent QLDPAF epitope but
lacking the small HBsAg show efficient cell attachment.
Interestingly, beads conjugated with particles containing the
whole repertoire of the surface proteins were twice as much
active compared to preS1 alone. Thus, it appears that HBVis a multivalent ligand containing at least two separate
determinants that synergistically act to mediate effective
cell attachment.
The number of the small HBsAg epitopes per particle is
much higher than that of the preS1 QLDPAF attachment
epitopes (a ratio of about 50 to 1, respectively). Also, it
appears that the small HBsAg epitope recognizes a more
general cell surface component, whereas the preS1 epitope
binds a liver specific receptor [8]. The HBsAg epitope
therefore is expected to readily attach cells; however,
operative attachment is accomplished only in the presence
of receptors that specifically interact with the preS1 epitope.
According to this model, the HBsAg functions in scanning
the appropriate target cells.
Multivalent cell attachment appears to be adopted by
many viruses along evolution [29]. Upon binding to the first
receptor, the searching for the second receptor becomes
more efficient as it is performed in two rather than three
dimensions. The virus might bind weakly to an abundant
receptor through the first epitope. By making and breaking
such weak bonds, the virus browses over the surface of a
cell until the second epitope interacts with its cognate
receptor to commence infection.5. Duck HBV and cell attachment/infection
In the absence of animal models for HBV, the duck HBV
(DHBV) turned out to be a fruitful animal model. As all
hepadnaviruses exhibit some sequence similarity at the level
of amino acid and share similar genome organization and
virion structure, the data on DHBV may be, at least in part,
relevant to HBV and vise versa. Unlike HBV, DHBV
expresses only two envelope proteins from a single open
reading frame (Fig. 1). The amino-terminal region of the
large envelope protein (L) referred to as preS is not found in
the smaller (S) protein. Upon transfection, DHBV can be
propagated in human hepatoma cell lines [30], but DHBV
infects only duck hepatocytes. Thus, the early events in
DHBV infection including cell attachment are regulated by
species-specific factors. The DHBV preS region is of 161
amino acids and is sufficient to compete out DHBV infec-
tion. Based on this behavior and other studies, it became
evident that the preS region is directly involved in cell
attachment and receptor recognition. In this regard, DHBV
preS region is functionally similar to the preS1 region of the
HBV envelope protein. No direct and quantitative measure-
ments were performed for the capacity of the DHBV smaller
envelope protein to bind cells. However, it has been
demonstrated by competition analysis that the small S
protein has a minor role [11].
To date, we have no information on the putative HBV
receptor. The discovery of gp180 as a putative cellular
receptor for DHBV was rewarding and instrumental in
resolving some of the early steps in DHBV infection.
gp180 is encoded by the duck carboxypeptidase D (duCPD)
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the interaction of the DHBV preS with duCPD revealed a
relatively broad region in preS that mediates DHBV attach-
ment, amino acid residues 30–115. This region was further
subdivided into distinct preS domains with diverse affinities
but all display cooperative and sequential interactions with
duCPD. Based on these studies, it has been proposed that
the three-dimensional structure rather than primary preS
sequence determines effective receptor interaction. Initially,
a primary attachment site forms a complex with the receptor
that triggers the second unstructured site to adapt a high-
affinity binding structure [13,32]. However, as gp180 exhib-
its no liver-specific expression and is incapable of rendering
non-susceptible cell lines infectable [33], one has to con-
clude that gp180 although may be required is not sufficient
for DHBV infection. Identification of additional DHBV
preS binding proteins, such as p120 and p55, lends further
support to this notion [34,35].
Studies of the early steps in hepadnavirus infection at the
molecular level are now starting to illuminate the mecha-
nisms underlying their strict species specificity. Specifically,
the basis for host-discrimination between two of the avian
hepadnaviruses, namely, the duck and the heron viruses
(DHBV and HHBV, respectively) has been investigated.
Primary duck hepatocytes are permissive to HHBV replica-
tion following transfection with the viral genome, but are
refractory to HHBV infection [13,33,36]. Thus, host-dis-
crimination between these viruses is believed to be deter-
mined at the level of virus entry. Accordingly, pseudotyping
HHBV with DHBV envelope proteins rendered the virus
infectious to primary duck hepatocytes [36]. Further analy-
ses using subdomain pseudotyping and competition experi-
ments excluded a predominant role for the gp180 binding
subdomain of preS in host discrimination. Instead, a sub-
domain encompassing amino acids 20–40 of preS was
assigned as the host-discriminatory determinant [36,37].
Oddly, a myristoylated peptide spanning the host-discrimi-
natory subdomain from HHBV preS blocks infection of
primary duck hepatocytes by DHBV, possibly at the level of
viral attachment [37]. In light of this, the observation that
HHBV does not infect primary duck hepatocytes may be
explained by lack of interaction or modification (i.e., pro-
teolysis) involving the host-discriminatory subdomain in a
stage later than attachment. Host specificity among avian
hepadnaviruses may be thus determined at a post-attach-
ment, pre-transcriptional level, along the early steps of
infection.6. Uptake route for hepadnaviruses
Data concerning the early, post-attachment steps in
hepadnaviral entry is largely limited to studies performed
with DHBV in primary duck liver hepatocytes. Initially,
efforts were largely focused on determining the pH depen-
dency of the hepadnaviral uptake. This criterion is oftenused to classify viral uptake into either one of two strate-
gies, namely, direct fusion of the viral envelope with the
plasma membrane (pH independent) or a low-pH triggered
fusion with the endosomal membrane following endocyto-
sis of the viral particle (pH dependent) [38]. Studies aimed
to investigate this issue with respect to hepadnaviruses all
used lysosomotropic agents (e.g., ammonium chloride) but
reached divergent conclusions [39–42]. This discrepancy
possibly resulted from the variable experimental conditions
and the different methodologies of analysis employed in
these studies. Thus, despite the fact that the majority of
these studies suggested a pH-independent entry for the virus
[39,41,42], conclusions based on these studies should be
taken with caution. Furthermore, several observations ac-
cumulated to date infer that moderately low pH possibly
remaining in the presence of lysosomotropic agents [43],
may still play a role in hepadnaviral entry. It has been
demonstrated that DHBV uptake requires endocytosis
[39,44], a feature usually associated with a low pH-trig-
gered fusion mechanism [38]. Also, exposure of DHBV
particles to low pH was shown to induce a conformational
change in the viral large surface protein resulting in
increased hydrophobicity of the virus surface (see below).
Finally, acidic conditions were shown to enhance infectivity
of protease-treated HBV particles (see below). Altogether,
while a strict low pH dependency may not apply to
hepadnaviruses to the same extent as for certain other
viruses, low pH may still significantly facilitate entry of
the virus.
Remarkably, low pH-induced conformational changes of
the large surface protein may not only assist the virus in
membrane fusion [43] but may also facilitate nucleocapsid
release in the consecutive steps of viral entry. The large
surface protein assumes either one of two major topologies
in the envelope of mature virions [45–48]. In one topology,
the preS domain is displayed on the virus surface while in
the other, the same domain is sequestered inside the virus
lumen. The internally sequestered preS domains are be-
lieved to form a matrix that interacts with the nucleocapsid
[1]. It was demonstrated that exposing the virus to low pH
triggers translocation of the internally sequestered preS
domains onto the viral surface [46,47]. Thus, exposure of
the virus to low pH in the endosome may allow dissociation
of the enclosed nucleocapsid from the preS matrix, facili-
tating its release following membrane fusion.
The discovery of gp180 as a cellular receptor for DHBV
greatly facilitated studying the intracellular traffic of the
incoming virus. gp180 cycles between the trans-Golgi
network (TGN) and the plasma membrane, predominantly
maintaining a TGN localization at steady state [33,49].
Sorting of the protein involves passage through early and
possibly late endosomes en route the TGN [44,50], and is
controlled by its cytoplasmic domain that harbors a putative
phosphorylation site for casein kinase [44,51,52]. The role
of gp180 in post-attachment steps of DHBV entry was first
demonstrated by the observation that expression of the full-
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line Huh7 resulted in internalization of the virus into these
cells, whereas expression of a truncated form lacking its
cytoplasmic domain arrested viral uptake at the cell surface
[33]. This observation was in accord with the role of the
gp180 cytoplasmic domain in retrieval of the protein from
the plasma membrane [51,52]. Importantly, virus internal-
ized following expression of the full-length form of gp180
retained an endosomal localization and was not delivered to
the TGN [33], inferring that in susceptible hepatocytes,
fusion may occur through this compartment. A subsequent
study in primary duck hepatocytes showed that overexpres-
sion of gp180 mutated in the putative phosphorylation site
reduced infection by DHBV, presumably due to lysosomal
sorting of the virus–receptor complex [44]. Collectively,
accumulative data confer a role for gp180 in early, post-
attachment trafficking of the virus. It should be noted,
however, that gp180 expression by itself does not confer
susceptibility on otherwise non-susceptible, permissive cells
[33]. Since gp180 suffices for DHBV internalization into
endosomes, it is therefore likely that other, additional co-
receptors are necessary for later stages of infection, possibly
for membrane fusion.
A successful interaction of the major HBV–cell attach-
ment epitope with its cognate cellular receptor has to trigger
some downstream physiological changes that culminate in
endocytosis. A synthetic epitope conjugated to a synthetic
bead retained not only the proper cell attachment capacity
but also uptake (Fig. 2). It is therefore very likely that the
sole interaction with the cellular receptor sufficed to activate
some downstream effectors that regulate endocytosis. Iso-Fig. 2. Attachment and uptake of synthetic beads coated with HBV sub-vira
visualization of a late stage (A) and completion (B and C) of an SVP-conjugated be
G) Scanning electron microscopy (SEM) visualization of different stages in attaclation and characterization of the putative HBV receptors
should be of great importance to challenge this interesting
possibility.7. Membrane fusion
Based on sequence analysis, Rodriguez-Crespo et al. [53]
have found a hydrophobic stretch of 23 amino acids at the N
terminus of the small HBV surface (S) open reading frame
that was tentatively assigned as a fusion peptide. Noticeably,
the peptide overlaps the first transmembrane domain (TM1)
of the surface antigen (Fig. 1). Comparative analysis revealed
that the sequence of the peptide is highly conserved between
different HBV subtypes and to a lesser degree, between
different members of the hepadnavirus family, the substitu-
tions being mostly conservative. Notably, the hepadnaviral
sequences share elements conserved in fusion peptides of all
paramyxoviruses and some retroviruses, including HIV-1,
HIV-2 and SIV. Also, secondary structure prediction for the
sequence located C-terminally to the putative fusion peptide
implied that this region adapts an a-helical conformation that
harbors bulky, hydrophobic residues at every fourth and third
positions in an alternate fashion [54]. Such a heptad repeat
motif is implied in formation of coiled coils typically found
in viral fusion and intracellular vesicle transport (vSNARE-
tSNARE) complexes [55,56].
Subsequent experimental data strongly supported a role
for the candidate peptides in membrane fusion during
hepadnaviral entry. The fusogenic properties of the peptides
were demonstrated in vitro by means of vesicle aggregation,l particles (SVPs) [8]. (A–C) Transmission electron microscopy (TEM)
ad engulfment by the cell membrane. B is a higher magnification of C. (D–
hment and uptake of SVP-conjugated beads (D–G).
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[54,57]. Pre-treating HBV and woodchuch HBV (WHV)
with V8 protease that cleaves adjacent to the putative
fusogenic peptides significantly enhanced the infectivity of
the respective viruses in the hepatoblastoma cell line HepG2
[58,59]. Cleavage by V8 protease was suggested to expose
the putative fusion peptides under the proper environmental
conditions, in analogy with processing of other viruses (e.g.,
cleavage of the influenza HA into HA1 and HA2). Remark-
ably, infectivity of the protease-treated viruses was further
enhanced by acidic conditions, in consistence with the
notion that low pH facilitates virus entry (see above). It
should be noted, however, that cleavage at this position
resulted in loss of the preS domains, leading to loss of tissue
specificity of the virus [60]. Therefore, in the context of
viral infection in vivo, this may be settled only if a similar
cleavage occurs subsequent to preS-mediated attachment of
the virus to the hepatocyte cell membrane.
Studies made with DHBVoffer an alternative mechanism
underlying exposure of the fusogenic peptide during infec-
tion. The proposed mechanism is based on the identification
of a previously unrecognized fold for the viral surface
proteins in which the region connecting the two transmem-
brane domains (TM1 and TM2) is membrane-traversing,
conferring some of the large envelope proteins with a
spring-loaded, metastable structure [61]. It was found that
this structure goes through a conformational change upon
exposure of DHBV subviral particles to low pH, releasing
TM1 onto the particle surface [43]. Release of TM1 was
shown to render these particles hydrophobic based on their
aggregative behavior and their liposome binding activity.
Furthermore, DHBV virions were inactivated following a
similar low pH pre-treatment, substantiating a role for this
conformational change in the natural course of infection.
Overall, these observations suggest that, similar to other
viruses [62], a mechanism exists for DHBV by which the
viral envelope protein is being released from a preactivated,
metastable state into a fusion-active form, given the appro-
priate conditions. Noticeably, low pH was shown to trigger
this mechanism, in accordance with its possible role in virus
entry (see above).8. Nuclear import of the viral genome
Very little information exists regarding the post-fusion
events in the hepadnaviral entry. The viral genome must be
transported to the nucleus, where it is transcribed. Remark-
ably, endocytic entry gained by the virus may facilitate its
trafficking through the crowded environment of the cyto-
plasm and toward the nucleus [63–65]. Along the same line,
to ensure productive infection, the virus likely engages a
nuclear import machinery following exit from the endocytic
vesicle [63]. The core particle encapsulating the viral
genome is a prominent candidate for mediating post-fusion,
genome nuclear transport. The core protein contains nuclearlocalization signals (NLSs) at its highly basic C terminus
[66,67] and has been shown to bind the hepatocyte nuclear
membrane [68]. Escherichia coli-derived core particles were
shown to directly bind the NPC in a core phosphorylation-
and importin-dependent manner [3]. Core phosphorylation
was presumed necessary to expose C-terminally disposed,
luminally sequestered NLSs onto the capsid surface. Inter-
estingly, core phosphorylation was also shown to interfere
with the nucleic acid binding activity of core [69]. There-
fore, core phosphorylation may play a dual role during the
initial stages of infection, promoting both the nuclear
targeting and release of the viral genome. Such a model
seems particularly attractive in light of the fact that the 30-
nm viral capsid may be too large to transverse the nuclear
pore itself. More work, however, is required to directly link
the above observations to the natural delivery of the viral
genome into the host nucleus.9. Conclusions and future perspective
Attachment of HBV to target cells is the very first step in
infection. A major epitope was identified that is not only
required but also sufficient to mediate efficient cell attach-
ment. The tiny genome of the virus with overlapping open
reading frames makes the HBV genome one of the most
compact genomes. Consequently, random sequence alter-
ation is practically rare. As a result, the integrity of this
major cell-attachment epitope, which is rather simple and
readily accessible, is preserved. Despite the simple compo-
sition of this epitope, the identification of its cognate
cellular receptor has faced many difficulties. Therefore, it
might be that a naive model of one epitope–one receptor is
invalid in this case. Indeed detailed analysis revealed that
hepadnavirus attachment to the cell involves multiple com-
ponents on both the cell surface and the virus envelope. The
possibility that a complex of several proteins provides the
functional HBV receptor should be considered. It is hoped
that the recent progress in establishing cells that are effec-
tively HBV infected and the unique power to measure
quantitatively multivalent interactions in virus–cell attach-
ment will facilitate the study and the identification of the
HBV receptors. Obviously, identification of the cognate
cellular receptors is instrumental to resolve the mechanism
of HBV infection.
The basic rationale behind the molecular scenario of
HBV infection described in this review is that HBV infects
cells as a single virion. Several findings hint at the possi-
bility that this might not be the case and HBV infects cells as
a conglomerate of virions and subviral particles. According
to this hypothesis, HBV-infected cells overproduce subviral
particles to improve conglomerate formation and infection.
The finding that subviral particles improve DHBV infection
may support this notion [70]. A second supportive piece of
evidence comes from the study of HBV integrants in the
HCC cell line PLC/PRF/5. In these cells, a number of
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from different HBV subtypes [71]. Given the fact that these
cells were derived from a clonal tumor, one has to argue that
a single cell experienced repeated and multiple infections.
Alternatively, it is possible that all the different subtype
virions were the component of a given virion conglomerate
that originally infected this cell before its outgrowth as
HCC. Considering the problematic issue of HBV superin-
fection [72], we found the second possibility a more likely
one. Lastly, hepatitis delta virus (HDV) must infect and
propagate in HBV-positive cells for generation of mature
and infectious particles [73]. HDV is enveloped by HBV
envelope proteins and therefore expected to compete with
HBV infection for the very same set of receptors. This
competition in infection is deleterious for HDV that its
propagation depends on the envelope proteins supplemented
by the coinfected HBV. Our hypothesis that infection is
accomplished by virion conglomerate provides a reasonable
solution to this seemingly paradoxical behavior of HDV.
Virus–cell attachment is potentially susceptible to spe-
cific inhibitors. It is possible to block either the viral
attachment epitopes or the cellular cognate receptors. The
former approach is believed to be less toxic to the organism
and much more efficient but might be less effective for long-
term treatment as escaping mutants are expected to rise. The
quantitative assay for single cell attachment is expected to
facilitate the screening for and the evaluation of the effec-
tiveness of potential inhibitory drugs.References
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